As is known, Tat(48–57) neuroprotection in stroke models strongly depends on the route of administration of the peptide, e.g., in contrast to intraperitoneal delivery, the intracerebroventricular injection of this peptide enabled neuroprotection against cerebral ischemia [83,102]. This evidence concerns the gene TAT and Stroke.